Literature DB >> 21320021

Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).

Andrea B Flory1, Kenneth M Rassnick, Hollis N Erb, Laura D Garrett, Nicole C Northrup, Kim A Selting, Brenda S Phillips, Jennifer E Locke, John D Chretin.   

Abstract

OBJECTIVE: To evaluate factors associated with second remission in dogs with lymphoma retreated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol after relapse following initial treatment with a first-line 6-month CHOP protocol.
DESIGN: Retrospective case series. ANIMALS: 95 dogs with lymphoma. PROCEDURES: Medical records were reviewed. Remission duration was estimated by use of the Kaplan-Meier method. Factors potentially associated with prognosis were examined.
RESULTS: Median remission duration after the first-line CHOP protocol was 289 days (range, 150 to 1,457 days). Overall, 78% (95% confidence interval [CI], 69% to 86%) of dogs achieved a complete remission following retreatment, with a median second remission duration of 159 days (95% CI, 126 to 212 days). Duration of time off chemotherapy was associated with likelihood of response to retreatment; median time off chemotherapy was 140 days for dogs that achieved a complete remission after retreatment and 84 days for dogs that failed to respond to retreatment. Second remission duration was associated with remission duration after initial chemotherapy; median second remission duration for dogs with initial remission duration ≥ 289 days was 214 days (95% CI, 168 to 491 days), compared with 98 days (95% CI, 70 to 144 days) for dogs with initial remission duration < 289 days. CONCLUSIONS AND CLINICAL RELEVANCE: Findings suggested that retreatment with the CHOP protocol can be effective in dogs with lymphoma that successfully complete an initial 6-month CHOP protocol.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320021     DOI: 10.2460/javma.238.4.501

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

Review 1.  Species differences in tumour responses to cancer chemotherapy.

Authors:  Jessica Lawrence; David Cameron; David Argyle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

2.  3D-culture models as drug-testing platforms in canine lymphoma and their cross talk with lymph node-derived stromal cells.

Authors:  Ju Hyun An; Woo Jin Song; Qiang Li; Dong Ha Bhang; Hwa Young Youn
Journal:  J Vet Sci       Date:  2021-03-05       Impact factor: 1.672

3.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

4.  RNA disruption indicates CHOP therapy efficacy in canine lymphoma.

Authors:  Amadeo M Parissenti; Laura B Pritzker; Baoqing Guo; Rashmi Narendrula; Shirly Xiaohui Wang; Lin Laura Lin; Jingchun Pei; Karolina Skowronski; Dorothee Bienzle; J Paul Woods; Kenneth P H Pritzker; Brenda L Coomber
Journal:  BMC Vet Res       Date:  2019-12-16       Impact factor: 2.741

5.  Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas.

Authors:  Taismara K Garnica; Jéssika C C Lesbon; Ana C F C M Ávila; Arina L Rochetti; Oscar R S Matiz; Roana C S Ribeiro; Aline Zoppa; Adriana T Nishiya; Mirela T Costa; Andrigo B de Nardi; David J Argyle; Ricardo F Strefezzi; Juliano C Silveira; Heidge Fukumasu
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

6.  Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy.

Authors:  Paweł Klimiuk; Wojciech Łopuszyński; Kamila Bulak; Adam Brzana
Journal:  Animals (Basel)       Date:  2021-04-20       Impact factor: 2.752

7.  RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy.

Authors:  Miles W Mee; Sydney Faulkner; Geoffrey A Wood; J Paul Woods; Dorothee Bienzle; Brenda L Coomber
Journal:  BMC Res Notes       Date:  2022-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.